Clinical trial
A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After…
NCT00189254 · MEDA Pharma GmbH & Co. KG, Industry · Completed
Key facts
| NCT number | NCT00189254 |
|---|---|
| Title | A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ |
| Official title | A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1487-IMIQ Study |
| Lead sponsor | MEDA Pharma GmbH & Co. KG, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Actinic Keratoses |
| Intervention type | Drug |
| Interventions | Imiquimod |
| Enrollment | 72 |
| Start date | Apr 1, 2005 |
| Primary completion | Nov 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Feb 7, 2022 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: